Report Highlights

India Paroxysmal Supraventricular Tachycardia Market: Market Overview

India's PSVT market is structured around three core pillars: acute pharmacological management using adenosine and verapamil, long-term antiarrhythmic therapy using beta-blockers and flecainide, and interventional electrophysiology via radiofrequency catheter ablation. Government policy has overwhelmingly shaped the pharmaceutical segment, where the Drug Price Control Order (DPCO) 2013, administered by the National Pharmaceutical Pricing Authority (NPPA), imposes ceiling prices on scheduled cardiac formulations. The private hospital sector — led by chains such as Apollo Hospitals, Fortis Healthcare, and Medanta — drives the procedural segment, largely independent of direct public funding except where Ayushman Bharat PM-JAY reimbursement applies to ablation packages defined under health benefit packages (HBPs).

Structurally, the market remains underpenetrated relative to PSVT prevalence. India carries an estimated burden of 2.9 million PSVT patients, yet fewer than 15% receive rhythm-specific diagnosis or sustained treatment. The Central Government Health Scheme (CGHS) provides cardiac drug reimbursement for central government employees but covers a narrow population. The Employees' State Insurance (ESI) scheme, administered by the Ministry of Labour and Employment, extends some cardiac coverage to formal sector workers, but formulary access for antiarrhythmics is inconsistent across ESI hospitals. These structural coverage gaps create a predominantly out-of-pocket market dynamic that currently limits uptake but simultaneously signals substantial latent demand once coverage expansion matures.

Policy-Driven Growth in PSVT Treatment in India

Three distinct policy mechanisms are actively driving PSVT market expansion. First, the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), administered by the National Health Authority (NHA), covers catheter ablation for supraventricular arrhythmias under cardiac surgery health benefit packages, with package rates revised upward in 2023 to approximately INR 95,000 per ablation procedure. This reimbursement mechanism directly expands the interventional cardiology addressable market by enabling tier-2 city hospitals empanelled under PM-JAY to offer electrophysiology studies and ablation without upfront patient cost barriers, generating measurable procedural volume growth at empanelled centres in states like Rajasthan, Madhya Pradesh, and Telangana.

Second, the NPPA's price regulation under DPCO 2013 suppresses drug prices for scheduled formulations, which paradoxically increases volume by improving affordability of adenosine injections and oral antiarrhythmics at the retail level. Third, the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), implemented through the National Health Mission (NHM), funds cardiac screening camps at community health centres. These camps identify undiagnosed arrhythmia patients and channel them into district-level care pathways, generating new diagnosed patient cohorts. The Ministry of Health and Family Welfare's 2023 revised NHM operational guidelines explicitly include electrocardiography as a mandated diagnostic tool at primary health centres, supporting earlier PSVT identification at scale.

Regulatory Barriers and Compliance Costs

The Central Drugs Standard Control Organisation (CDSCO), operating under the Drugs and Cosmetics Act 1940 and its 2017 Medical Devices Rules amendment, classifies electrophysiology catheters as Class C medical devices requiring mandatory Indian registration before commercial sale. The registration pathway demands local clinical data or a bridging study waiver, which CDSCO grants selectively. In practice, international catheter manufacturers such as Biosense Webster and Medtronic report 18-to-24-month registration timelines for new catheter models, during which competing older-generation products maintain market exclusivity. Import duties of 7.5% under the applicable customs tariff heading, combined with a 12% GST on medical devices, add approximately 20–22% to landed catheter costs relative to ex-factory price, directly constraining hospital procurement budgets and limiting procedural volume growth at cost-sensitive PM-JAY empanelled hospitals.

On the pharmaceutical side, the NPPA's market-based price regulation under paragraph 19 of DPCO 2013 applies ceiling prices to all scheduled drugs, calculated as a simple average of brands holding more than 1% market share. For antiarrhythmic formulations on the National List of Essential Medicines 2022 — which includes metoprolol, verapamil, and amiodarone — manufacturers cannot exceed notified ceiling prices without prior NPPA approval. Companies violating ceiling price provisions face recovery orders plus 15% interest under paragraph 20 of DPCO. Additionally, new drug approvals for novel antiarrhythmic molecules require CDSCO Phase III local clinical trial data under the New Drugs and Clinical Trials Rules 2019, adding 3–5 years and INR 15–40 crore in trial costs, creating high barriers for innovative pharmacological therapies seeking Indian market entry.

Policy-Created Opportunities in India's PSVT Market

The single largest policy-created opportunity lies within PM-JAY's ongoing empanelment expansion. The NHA's 2024 strategic roadmap targets empanelment of 30,000 hospitals by 2025, up from approximately 27,500 in mid-2024, with explicit priority for secondary cardiac care facilities in aspirational districts. Manufacturers of portable electrophysiology mapping systems and affordable single-use ablation catheters are positioned to benefit directly, as lower-cost device alternatives aligned with PM-JAY package rates become the purchasing preference for newly empanelled tier-2 and tier-3 hospitals. The Production Linked Incentive (PLI) Scheme for Medical Devices, administered by the Department of Pharmaceuticals under the Ministry of Chemicals, offers 5% incentive on incremental sales for domestically manufactured cardiac devices, incentivising local catheter assembly and reducing import dependency over the 2023–2028 scheme period.

A second distinct opportunity emerges from the CDSCO's accelerated approval pathway introduced under the New Drugs and Clinical Trials Rules 2019 for drugs already approved by reference regulators — the US FDA, EMA, Health Canada, TGA, or MHRA. Antiarrhythmic drugs newly approved by any two reference regulators within the preceding 24 months qualify for waiver of local Phase III trials, enabling 12-month Indian approval timelines instead of the standard 5-year pathway. This regulatory opening creates a commercially viable route for bringing newer agents such as vernakalant or ranolazine, with demonstrated PSVT utility, to Indian cardiologists — a pipeline opportunity that MNC pharmaceutical companies with existing Indian regulatory infrastructure are best positioned to exploit before domestic generics establish competitive pricing.

Market at a Glance

Leading Market Participants

• Sanofi India
• Abbott India
• Pfizer India
• Boston Scientific India
• Johnson & Johnson MedTech India
• Medtronic India
• Biosense Webster India
• Sun Pharmaceutical Industries
• Cipla Limited
• Lupin Limited

Regulatory and Policy Environment

The primary legislative framework governing PSVT treatment in India is the Drugs and Cosmetics Act 1940, as amended and supplemented by the New Drugs and Clinical Trials Rules 2019 and the Medical Devices Rules 2017, all enforced by CDSCO under the Ministry of Health and Family Welfare. Antiarrhythmic drugs fall under Schedule H of the Drugs and Cosmetics Rules 1945, requiring prescription-only dispensing. Price regulation operates separately under the Essential Commodities Act 1955 via DPCO 2013, with NPPA as the enforcement authority. The National List of Essential Medicines 2022 review added digoxin and retained metoprolol and amiodarone, directly subjecting these PSVT-relevant molecules to ceiling price controls and mandatory availability requirements at public facilities. CDSCO is expected to publish updated medical device classification amendments by late 2025 that may reclassify single-use electrophysiology catheters under a revised Class C sub-tier with streamlined post-market surveillance requirements.

Compared to regional peers, India's regulatory framework is more restrictive than China's NMPA fast-track pathway but more structured than Bangladesh or Pakistan, which lack dedicated cardiac device registration frameworks. India's requirement for local clinical data or bridging studies for Class C devices diverges from the ASEAN Medical Device Directive mutual recognition approach adopted by Singapore and Malaysia, creating market entry friction that disproportionately affects small innovative device companies. The Drugs Amendment Bill pending before Parliament as of 2024, which proposes consolidating medical device and pharmaceutical oversight under a unified regulatory authority, represents the most consequential anticipated structural change to the framework. If enacted before 2027, it would merge CDSCO's device and drug divisions, potentially accelerating approval timelines for combination cardiac diagnostic-therapeutic products that currently require dual pathway navigation.

Long-Term Policy Outlook for India's PSVT Market

By 2032, three policy shifts are expected to materially reshape India's PSVT market. The National Health Authority's expansion of PM-JAY benefit packages is projected to include implantable cardiac loop recorders for undiagnosed palpitation patients by 2027, opening a new diagnostic revenue stream. The Department of Pharmaceuticals' PLI Scheme Phase II, anticipated from 2026, is expected to extend incentives to single-use electrophysiology catheters manufactured in India, which would reduce import dependence and lower device costs at empanelled hospitals. Simultaneously, the NHM's cardiology integration roadmap under the Health and Wellness Centre (HWC) programme aims to deploy 12-lead ECG machines at all 1.5 lakh HWCs by 2027, creating the infrastructure for population-level arrhythmia screening that did not previously exist at primary care level.

The NPPA is expected to conduct a comprehensive DPCO revision by 2028, which analysts anticipate will bring additional cardiac combination formulations under scheduled price control, specifically fixed-dose combinations of antiarrhythmics with rate-controlling agents currently sold at unregulated market prices. This revision will compress margins for companies relying on premium-priced branded generics but will expand patient access and volume. The Make in India initiative's health sector component, coordinated through the Ministry of Commerce, is supporting two dedicated medical device manufacturing clusters in Andhra Pradesh and Uttar Pradesh that include cardiac device assembly units — these clusters are expected to produce commercially viable ablation catheter components by 2028, fundamentally altering the cost structure of the interventional PSVT segment and enabling Indian manufacturers to compete on price with imported systems for the first time.